Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
The drug discovery specialist Anagenex has sealed a collaboration pact with Nimbus Therapeutics to co-develop small molecule drugs with the help of artificial intelligence (AI).
The US Food and Drug Administration (FDA) has approved a topical foam developed by Arcutis Biotherapeutics and branded as Zoryve for the skin condition seborrheic dermatitis in people aged nine years and up.
A portfolio company created and incubated by Apple Tree Partners (ATP) has raised $52 million in series A funding to enable it to rapidly discover novel small molecule therapeutics.
Small molecule drugs are carving a significant niche in lung cancer treatment, according to data and analytics company, GlobalData, and Tagrisso is well on its way to dominating the market.
Exscientia plc will receive an upfront cash payment of $20 million from Merck KGaA, Darmstadt, Germany, as the companies collaborate plus potential payments of up to $674 million in aggregate.
The U.S. company Nimbus Therapeutics has raised $210 million in a financing round to fund the development of small molecule drugs powered by computational drug discovery.
The U.S. company Arthrosi Therapeutics has bagged $75 million in a Series D round to fund the clinical development of a small molecule drug for chronic gout.
Anebulo Pharmaceuticals is currently developing a new, first-of-its-kind drug, ANEB-001, intended to rapidly reverse the negative effects of acute cannabinoid intoxication (ACI) within one hour of administration. The treatment is a cannabinoid receptor...
The world’s first anti-fibrotic small molecule inhibitor, discovered and designed by generative artificial intelligence (AI) has completed the first patient dose in a phase 2 clinical trial.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Medicine developer, CatSci Ltd announced yesterday (March 15) that it has formed a new partnership with AGC Pharma Chemicals, a small molecule Contract Development and Manufacturing Organisation (CDMO).
BioNTech and Ryvu Therapeutics will collaborate to develop oncology programs, with the pair announcing that they will work together as part of a multi-target research collaboration.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
Bolstered by manufacturing advancements, the global revenues of the pharmaceutical excipients market are expected to grow at a CAGR of 5.8% in the coming years.
This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.
The CRO and software provider for small molecule discovery, Cresset, is collaborating with Elixir to create a new platform for efficient drug discovery.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
The record number of orphan drugs approved in Europe last year reflects the pharma industry’s need to refill pipelines and scientific advances says Genetic Alliance UK
Dispatches from the FT Global Healthcare and biotech conference
Catering for low value, high volume customers as well as the growing number of firms developing complex drugs will be a big challenge in the era of personalised medicine according to experts speaking at a London conference this week.
Biopharmaceutical firm Merck Serono will make small molecule drugs at the new plant it is building in China according to a company spokeswoman, who told us the firm will supply both local and international markets.
The complex nature of biopharmaceuticals dictates the choice of contract manufacturer when compared with selecting a partner for small molecule drugs, according to a life sciences consultant.
US contract services firm KBI Biopharma has begun using the PER.C6 platform for cell line generation as part of its offering to meet growing demand for biomanufacturing services.
The founder, chairman and chief executive of French drug delivery
company Flamel Technologies has been lambasted by disgruntled
shareholders who want to bring in a new management team, writes
Phil Taylor.
